Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
820.00    -11.00 (-1.32%)
Bid:
816.00
Ask:
822.00
Spread: 6.00 (0.735%)
Market Cap: £774.61m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

11 Jan 2024 07:00

RNS Number : 3134Z
Polar Capital Holdings PLC
11 January 2024
 

11 January 2024 Polar Capital Holdings plc

AuM Update

 

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides its regular quarterly update of its unaudited statement of its Assets under Management ("AUM") and performance fees earned for the financial year to 31 March 2024.

 

Group AUM (unaudited)

 

Polar Capital reports that as at 31 December 2023, AuM were £19.6bn compared to £19.2bn at the end of March 2023, an increase of 2% over the period. During the nine-month period the £400m increase in AuM resulted from a £2.1bn increase relating to market movement and fund performance offset by net redemptions of £1.7bn.

 

AuM movement in nine months to 31 December 2023

Open ended

funds

Investment

Trusts

Segregated mandates

Total

AuM at 1 April 2023

£14,281m

£3,910m

£1,029m

£19,220m

Net flows

£(1,375)m

£(113)m

£(181)m

£(1,669)m

Fund closures1

£(7)m

-

£(43)m

£(50)m

Market movement

and performance

£1,336m

£705m

£18m

£2,059m

Total AuM at

31 December 2023

£14,235m

£4,502m

£823m

£19,560m

1 Return of funds to investors on closure of the Melchior European Absolute Return fund (Q1) and related segregated mandate (Q2).

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits (after the deduction of staff interests) earned in the first nine months of the Group's financial year.

 

Performance fee profit

net of staff allocations

Nine months to

31 Dec 22

Year to

31 Mar 23

(year-end)

Nine months to

31 Dec 23*

Net performance fee profit

£1.9m

£1.7m

£9.6m*

 

\* The figures to December 2023 are enhanced by what is expected to be approximately £0.6m of net deferment adjustments.

 

Gavin Rochussen, Chief Executive, commented:

 

"A strong rally in all major indices in the final calendar quarter of 2023, meant that our AuM at the end of the nine-month period were £19.6bn compared to £19.1bn at the end of the previous quarter and £19.2bn at the end of March 2023, despite net outflows over the period.

 

"In the quarter we benefited from continued net inflows of £45m into the Emerging Markets and Asian Stars funds and £28m into the Smart Energy Fund.

 

"Despite global equity markets rallying in the final quarter, the 'risk-off' stance by investors resulted in net outflows in the quarter of £1.1bn as clients reduced their weighting to active equities, taking profits in many cases following a strong period of performance. Net outflows for the nine months amounted to £1.7bn.

 

"In the quarter several clients continued to reduce their exposure to equities generally, directly impacting several Polar Capital funds including the Biotechnology Fund (£311m) and UK Value Fund (£238m) despite impressive absolute fund performance and strong performance relative to benchmark. Investors also continued to reduce weightings in our Technology funds and the European Opportunities Fund with net outflows of £136m and £230m in these strategies respectively. Overall, redemptions were concentrated in terms of number of clients, as opposed to representative of a wider trend.

 

"With peak interest rates in sight and declining inflation rates, investors will, we believe, begin to seek additional exposure to equities. We have a strong pipeline of client interest and have capacity to meet investor demand for our specialist active fund strategies. At the end of the quarter, we launched a Financial Credit Fund, managed by our Financials team, to further add to our offering.

 

"Performance fee profits, net of staff allocations, amounted to £9.6m compared to £1.7m in the prior year. While four funds earned a performance fee, most of the amount related to one fund.

 

"Long term performance remains strong with 81% of AuM outperforming respective benchmarks since inception.

 

"We remain confident that with our diverse range of differentiated, active specialist fund strategies we are well-positioned to perform for our clients and shareholders over the long term."

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)

Samir Ayub (Finance Director)

 

+44 (0)20 7227 2700

Numis Securities Limited - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

Stephen Westgate

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

John Welch

Sam Milford

 

+44 (0)20 3597 8680

 

Camarco

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

 

+44 (0)20 3757 4995

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBMMPTMTJBBAI
Date   Source Headline
1st Jul 202111:07 amRNSDividend Declaration
1st Jul 202110:26 amRNSDirector Declaration
1st Jul 20217:00 amRNSGroup Audited Results for year ended 31 March 2021
29th Jun 20213:53 pmRNSForm 8.3 - Ultra Electronics Holdings PLC
7th Jun 20217:00 amRNSNotice of Results
1st Jun 20217:00 amRNSTotal Voting Rights
26th May 20215:35 pmRNSDirector/PDMR Shareholding
21st May 20212:21 pmRNSDirector/PDMR Shareholding
20th May 202111:36 amRNSIssue of Equity
20th May 202110:38 amRNSHolding(s) in Company
19th May 20217:00 amRNSForm 8.3 - Immunodiagnostic Systems Holdings PLC
17th May 202112:45 pmRNSDirector/PDMR Shareholding
17th May 20217:00 amRNSDirector/PDMR Shareholding
17th May 20217:00 amRNSIssue of Equity
16th Apr 20217:00 amRNSDirector/PDMR Shareholding
15th Apr 20217:00 amRNSAuM Update
13th Apr 20214:27 pmRNSHolding(s) in Company
1st Apr 202110:44 amRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSTotal Voting Rights
25th Mar 20215:45 pmRNSHolding(s) in Company
18th Mar 20214:08 pmRNSHolding(s) in Company
1st Mar 20217:00 amRNSCompletion of Dalton SP LLP Acquisition
26th Feb 20214:33 pmRNSDirector/PDMR Shareholding
26th Feb 20214:32 pmRNSTotal Voting Rights
23rd Feb 20217:00 amRNSIssue of Equity
1st Feb 20215:35 pmRNSIssue of Equity
1st Feb 20217:00 amRNSBlock listing Interim Review
1st Feb 20217:00 amRNSTotal Voting Rights
25th Jan 20217:00 amRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSIssue of Equity
20th Jan 20215:25 pmRNSDirector/PDMR Shareholding
20th Jan 20215:22 pmRNSIssue of Equity
19th Jan 20219:39 amRNSIssue of Equity
18th Jan 20217:00 amRNSDirector/PDMR Shareholding
15th Jan 20217:00 amRNSIssue of Equity
14th Jan 20217:00 amRNSAuM Update
17th Dec 20207:00 amRNSAcquisition of Dalton Strategic Partnership LLP
4th Dec 202010:08 amRNSIssue of Equity
1st Dec 20207:00 amRNSTotal Voting Rights
25th Nov 20203:36 pmRNSIssue of Equity
19th Nov 20207:00 amRNSUnaudited interim results
16th Nov 20202:13 pmRNSForm 8.3 - CPL RESOURCES PLC
2nd Nov 20208:51 amRNSTotal Voting Rights
23rd Oct 20204:26 pmRNSNotice of Results
19th Oct 20207:00 amRNSTeam Acquisition Completion
8th Oct 20204:48 pmRNSIssue of Equity
8th Oct 20207:00 amRNSAuM Update
29th Sep 202012:19 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.